Evidence map›Paper›PMID 30251010›Full record

Trial reportInternational urology and nephrology2018

Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients.

Melika Fallah, Gholamreza Askari, Alireza Soleimani, Awat Feizi, Zatollah Asemi

RetractedAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Antioxidants for adults with chronic kidney disease.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Coenzyme QAntioxidants (Basel, Switzerland) · 2020
    Review
  9. The impact of coenzyme QEndocrinology, diabetes & metabolism · 2020
    Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Melika FallahDepartment of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Gholamreza AskariDepartment of Community Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. askari@mui.ac.ir.
Alireza SoleimaniDepartment of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Awat FeiziIsfahan Endocrine and Metabolism Research Center, Isfahan, Iran.
Zatollah AsemiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe current study was conducted to determine the effects of coenzyme Q10 (CoQ10) supplementation on glycemic control and markers of lipid profiles risk in diabetic hemodialysis (HD) patients.

methodsThis randomized, double blind, placebo-controlled clinical trial was performed among 60 diabetic HD patients. Subjects were randomly allocated into two groups to take either 120 mg/day of CoQ10 supplements or placebo (n = 30 each group) for 12 weeks.

resultsAfter 12 weeks of intervention, CoQ10 supplementation, compared with the placebo, resulted in a significant decrease in serum insulin concentrations (- 2.5 ± 4.0 vs. + 2.8 ± 5.3 µIU/mL, P < 0.001), homeostasis model of assessment-estimated insulin resistance (- 0.9 ± 2.1 vs. + 1.2 ± 3.0, P = 0.002), and significant increase in the quantitative insulin sensitivity check index (+ 0.009 ± 0.01 vs. - 0.02 ± 0.05, P = 0.003). In addition, a trend toward a greater decrease in serum triglycerides (- 5 ± 53 vs. + 17 ± 44, P = 0.078) and VLDL-cholesterol levels (- 0.9 ± 10 vs. + 3 ± 9, P = 0.078) was observed in the CoQ10 group compared to the placebo group. We did not observe any significant effect of CoQ10 supplementation on fasting glucose, HbA1c and other lipid profiles compared with the placebo.

conclusionsOverall, our study supported that CoQ10 supplementation to diabetic HD patients for 12 weeks had beneficial effects on markers of insulin metabolism, but did not affect fasting glucose, HbA1c, and lipid profiles. Clinical registration http://www.irct.ir : IRCT2016081811763N30.

Indexed as

Dietary SupplementsRenal DialysisAdultAgedBlood GlucoseDiabetes ComplicationsDouble-Blind MethodFemaleGlycated HemoglobinHumansInsulinInsulin ResistanceKidney Failure, ChronicLipidsMaleMiddle AgedBlood Glucosecoenzyme Q10Glycated Hemoglobinhemoglobin A1c protein, humanInsulinLipidsTriglyceridesUbiquinoneVitaminsCoenzyme Q10 supplementationGlycemic controlHemodialysisLipid profiles

Identifiers

PMID30251010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.